title: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.
abstract: OBJECTIVE
  Allelic loss of chromosome 1p is a powerful predictor of tumor chemosensitivity and prolonged survival in patients with anaplastic oligodendrogliomas. Chromosome 1p loss also occurs in astrocytic and oligoastrocytic gliomas, although less commonly than in pure oligodendroglial tumors. This observation raises the possibility investigated in this study that chromosome 1p loss might also provide prognostic information for patients with high-grade gliomas with astrocytic components.
  
  
  METHODS
  The authors report on seven patients with high-grade gliomas composed of either pure astrocytic or mixed astrocytic-oligodendroglial phenotypes, who had remarkable neuroradiological responses to therapy or unexpectedly long survivals. All of the tumors from these seven patients demonstrated chromosome 1p loss, whereas other genetic alterations characteristic of high-grade gliomas (p53 gene mutations, EGFR gene amplification, chromosome 10 loss, chromosome 19q loss, or CDKN2A/p16 deletions) were only found in occasional cases. The authors also assessed the frequency of chromosome 1p loss in a series of anonymous high-grade astrocytoma samples obtained from a tumor bank and demonstrate that this genetic change is uncommon, occurring in only 10% of cases.
  
  
  CONCLUSIONS
  Although any prognostic importance of chromosome 1p loss in astrocytic or mixed astrocytic-oligodendroglial gliomas can only be determined in larger and prospective series, these findings raise the possibility that some high-grade gliomas with chromosome 1p loss, in addition to pure anaplastic oligodendrogliomas, may follow a more favorable clinical course.
authors.affiliation: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Ino
authors.forename: M C
authors.initials: MC
authors.lastname: Zlatescu
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: D R
authors.initials: DR
authors.lastname: Macdonald
authors.forename: A O
authors.initials: AO
authors.lastname: Stemmer-Rachamimov
authors.forename: S
authors.initials: S
authors.lastname: Jhung
authors.forename: D A
authors.initials: DA
authors.lastname: Ramsay
authors.forename: A
authors.initials: A
authors.lastname: von Deimling
authors.forename: D N
authors.initials: DN
authors.lastname: Louis
authors.forename: J G
authors.initials: JG
authors.lastname: Cairncross
mesh_terms: D000328:Adult; D000483:Alleles; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology*; D002878:Chromosomes, Human, Pair 1; D005260:Female; D017353:Gene Deletion; D005787:Gene Frequency; D005819:Genetic Markers; D005909:Glioblastoma / Q000235:genetics; D005910:Glioma / Q000235:genetics* / Q000473:pathology*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D005819:Genetic Markers